The Switzerland market shrugged off early weakness and moved modestly higher on Friday, tracking positive global cues. Investors continued to cheer Swiss National Bank's interest rate move, in ...

Imexpharm's high-tech antibiotic factory IMP4 meets EU-GMP standards In 2023 ... In 2023, Imexpharm has 93 R&D projects, with 15 products have been launched on the market that year, enhancing its ...

As global markets react positively to China's new stimulus measures, the Hong Kong market has seen a significant uptick, with technology stocks particularly benefiting from the renewed investor ...

Yuan Longping High-Tech Agriculture Co., Ltd. engages in the process and sale of agricultural by-products. Its business activities include cultivating, reproducing, popularizing, and marketing of ...

Under the terms of this agreement, Biocon will develop and manufacture the products, and Tabuk Pharmaceuticals will hold the ...

The rise of digitalisation and technological advancements has significantly transformed the logistics landscape, particularly ...

This trend is being paid attention by Vietnamese pharmaceutical enterprises to develop and apply sci-tech, and offer technical and management ... Capable companies would need to invest in researching ...

Imexpharm's high-tech antibiotic factory IMP4 meets EU-GMP standards ... In 2023, Imexpharm managed 93 R&D projects, launching 15 new products to the market, thereby enhancing its portfolio of ...

Imexpharm’s high-tech antibiotics factory, IMP4, meets EU-GMP standards ... In 2023, Imexpharm had 93 R&D projects, with 15 products launched to the market, enhancing its portfolio of new ...